Scynexis is recalling two lots of Brexafemme (ibrexafungerp) tablets 150 milligram, 4 count cartons. The antifungal drug is approved for vulvovaginal candidiasis.
The possible cross-contamination risk is with ezetimibe, a non-antibacterial beta-lactam compound that could lead to swelling, rash, hives, anaphylaxis and a life-threatening reaction, according to the FDA. No adverse events have been reported.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
